TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16038912

Group type: EXPERIMENTAL
Intervention: TO+++ (therapeutic objective attained in all 3 years, n=145)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: TO intermediate (therapeutic objective attained only part of the time, n=256)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: TO--- (therapeutic objective never attained, n=178)
Number of subjects: 579
Study: 12528105

Group type: COMPARATOR
Intervention: Methotrexate alone (MTX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methotrexate and intraarticular corticosteroids (MTX + IAST)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard therapy (after 3 months for both groups)
Number of subjects: 40
Study: 10494965

Group type: EXPERIMENTAL
Intervention: New split influenza vaccine derived from BV-5F1 cell line
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8558199

Group type: EXPERIMENTAL
Intervention: N4-behenoyl-1-beta-D-arabinosylcytosine (BHAC)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Cytarabine
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Ubenimex
Number of subjects: 326

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 326
Study: 1878535

Group type: EXPERIMENTAL
Intervention: Diltiazem 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem (various doses)
Number of subjects: 8
Study: 6415780

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg every 12 hr for five days)
Number of subjects: 8721

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 8721

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 8721

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8721

Group type: EXPERIMENTAL
Intervention: Second cycle of minocycline followed by group C polysaccharide vaccine
Number of subjects: 8721
Study: 30462830

Group type: EXPERIMENTAL
Intervention: Galcanezumab treatment
Number of subjects: 1434
Study: 29907485

Group type: EXPERIMENTAL
Intervention: MCV (measles-containing vaccine)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: MCV2 (second dose of measles-containing vaccine)
Number of subjects: 684
Study: 27631634

Group type: EXPERIMENTAL
Intervention: Epidural (EP) administration of ropivacaine every 6 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion (SC) of ropivacaine after a bolus dose for 48 hours
Number of subjects: 18
Study: 25430900

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/Brimonidine 0.2% (BBFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brinzolamide 1% plus Brimonidine 0.2% (BRINZ + BRIM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both BBFC and BRINZ + BRIM
Number of subjects: 0
Study: 22616930

Group type: EXPERIMENTAL
Intervention: Repair with P90 System Adhesive Self‐Etch Primer and Bond and Filtek P90 Low Shrink Posterior Restorative
Number of subjects: 100

Group type: COMPARATOR
Intervention: Repair with Adper SE Plus and Filtek P60 Posterior Restorative
Number of subjects: 100
Study: 19829110

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (TGC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control of cardiovascular risk factors
Number of subjects: 3
Study: 17427615

Group type: EXPERIMENTAL
Intervention: Well-equipped eye tray including fluorescein dye, materials for irrigation and foreign body removal, a short‐acting mydriatic agent, and topical anesthetics and antibiotics; prepared in advance for eye injuries.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eye patching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary prevention and patient counseling on proper eye protection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate personal protection against laser use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sun protection and safety counseling for outdoor workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contact lenses
Number of subjects: 0
Study: 16470428

Group type: EXPERIMENTAL
Intervention: All-polyethylene (AP) tibial components
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metal-backed (MB) tibial components
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 12452939

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Omeprazole (20 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Number of subjects: 229
Study: 10723898

Group type: EXPERIMENTAL
Intervention: Stiffening overtube
Number of subjects: 232

Group type: COMPARATOR
Intervention: No overtube (control group)
Number of subjects: 232
Study: 8530244

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 24
Study: 1837825

Group type: EXPERIMENTAL
Intervention: Cumulative task sequencing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interspersal task sequencing
Number of subjects: 20
Study: 7061155

Group type: COMPARATOR
Intervention: High-grade purity ampicillin (less than 0.1 microgram antigen per gram)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slightly contaminated ampicillin (1.5 microgram antigen per gram)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of high molecular weight proteinaceous impurities (0.1-10 micrograms of antigen) in rabbits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated subcutaneous injections of high molecular weight proteinaceous impurities in rabbits
Number of subjects: 0
Study: 31342840

Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30099602

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 186

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and G-CSF
Number of subjects: 186
Study: 27522250

Group type: EXPERIMENTAL
Intervention: Formal attire
Number of subjects: 128

Group type: COMPARATOR
Intervention: Casual attire
Number of subjects: 128
Study: 25721187

Group type: EXPERIMENTAL
Intervention: Olanzapine/Fluoxetine combination (OFC) 6/25-12/50 mg/day
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Olanzapine/Fluoxetine combination (OFC)
Number of subjects: 255
Study: 23484632

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration during sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 21718520

Group type: EXPERIMENTAL
Intervention: Lumio loupe, digital camera, continuous feedback from Dermatologist
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard educational intervention (control group)
Number of subjects: 60
Study: 19884625

Group type: EXPERIMENTAL
Intervention: PDE‐5 inhibitors (sildenafil, vardenafil, tadalafil, mirodenafil, udenafil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choice of specific PDE‐5 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormonal blood tests or hormonal treatment
Number of subjects: 0
Study: 17333244

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (CHO trial; 0.7 g CHO kg(‐1) h(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water only (CON placebo trial)
Number of subjects: 10
Study: 15496345

Group type: EXPERIMENTAL
Intervention: Muscle relaxation therapy (once a week for a total of 4 times)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ordinary daily life in the reformatory (Control)
Number of subjects: 16
Study: 11185023

Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 144

Group type: COMPARATOR
Intervention: Telephone counseling
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: CO feedback (yes)
Number of subjects: 144

Group type: COMPARATOR
Intervention: CO feedback (no)
Number of subjects: 144
Study: 9008662

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg)
Number of subjects: 9
Study: 1286053

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.063% ropivacaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Epinephrine (1:200,000, 5 micrograms/ml)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ropivacaine with epinephrine (1%, 0.5%, and 0.25%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23

Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 23
Study: 3932048

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms q.i.d.
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms q.i.d.
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 30409776

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously with nivolumab 3 mg/kg intravenously on days 1 and 14, every 4 to 6 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Azacitidine and nivolumab therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pretherapy bone marrow and peripheral blood CD3 and CD8
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CTLA4 on CD4+ Teff
Number of subjects: 70
Study: 29737955

Group type: EXPERIMENTAL
Intervention: Breeza (flavored beverage)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Barium sulfate suspension
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Breeza
Number of subjects: 66
Study: 27036390

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 2 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg daily for 2 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cold compresses 2 times daily for 2 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 200
Study: 24742662

Group type: EXPERIMENTAL
Intervention: Self-titration algorithm adjusting lispro every day (Q1D)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Self-titration algorithm adjusting lispro every 3 days (Q3D)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Control (not specified, but implied as standard care)
Number of subjects: 1106
Study: 24106244

Group type: EXPERIMENTAL
Intervention: Azithromycin monotherapy, orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Azithromycin with rifampin, orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tulathromycin intramuscularly
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline intramuscularly (placebo)
Number of subjects: 120
Study: 20815872

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 18754834

Group type: EXPERIMENTAL
Intervention: Antidepressants given in addition to a mood stabilizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mood stabilizer alone
Number of subjects: 0
Study: 16897916

Group type: EXPERIMENTAL
Intervention: Automated Telephonic Data Collection (ATDC) system
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 398

Group type: COMPARATOR
Intervention: Face‐to‐face interview
Number of subjects: 398

Group type: COMPARATOR
Intervention: Written questionnaire
Number of subjects: 398
Study: 14632704

Group type: EXPERIMENTAL
Intervention: Secondary-primary care partnership education package, with four or more visits per year by diabetes specialist nurse, dietician, or chiropodist.
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (standard care without the education package).
Number of subjects: 411
Study: 11007104

Group type: EXPERIMENTAL
Intervention: Lactulose 30‐60 ml/day for three months (SHE‐L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (no lactulose, SHE‐NL)
Number of subjects: 40
Study: 8980598

Group type: EXPERIMENTAL
Intervention: Educational intervention in intervention communities
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 98
Study: 1632171

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fentanyl anaesthesia
Number of subjects: 18
Study: 6933705

Group type: EXPERIMENTAL
Intervention: 0.5% NaF solution rinsed once every 2 weeks for 3 years
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 0.2% NaF solution rinsed weekly
Number of subjects: 170

Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 170
Study: 31654784

Group type: EXPERIMENTAL
Intervention: WBRT (30 Gy in 10 fractions)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: WBRT (37.5 Gy in 15 fractions)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery alone
Number of subjects: 194
Study: 31563548

Group type: EXPERIMENTAL
Intervention: Cotton thread
Number of subjects: 200

Group type: COMPARATOR
Intervention: Polypropylene 0
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 200
Study: 29066245

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.04 mg kg−1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.5 mg kg−1)
Number of subjects: 12
Study: 25432953

Group type: EXPERIMENTAL
Intervention: Tailored print materials
Number of subjects: 192

Group type: COMPARATOR
Intervention: Generic print materials
Number of subjects: 192
Study: 24113432

Group type: EXPERIMENTAL
Intervention: Contrast medium with 300 mg iodine/ml
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Contrast medium with 370 mg iodine/ml
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-enhanced PET/CT
Number of subjects: 120
Study: 21859750

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg
Number of subjects: 618

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 618
Study: 19758618

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid intravenously every 3 months for 4 treatments
Number of subjects: 93

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 93
Study: 17764879

Group type: EXPERIMENTAL
Intervention: Tubulcus multilayer bandaging system (35 mm Hg)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Multilayer bandaging system with elastic bandages only (20 to 25 mm Hg)
Number of subjects: 138
Study: 16220284

Group type: COMPARATOR
Intervention: ESPrit 3G (W setting)
Number of subjects: 28

Group type: COMPARATOR
Intervention: ESPrit 3G (M setting)
Number of subjects: 28

Group type: COMPARATOR
Intervention: ESPrit 3G
Number of subjects: 28
Study: 14520518

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11561564

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and metronidazole 500 mg twice daily for one week (Group A)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus clarithromycin 250 mg and metronidazole 500 mg twice daily for one week (Group B)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for one week (Group C)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for 2 weeks (Group D)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 500 mg twice daily for 2 weeks (Group E)
Number of subjects: 253
Study: 7717629

Group type: EXPERIMENTAL
Intervention: Cochlear implants (Ineraid, Nucleus, or 3M/Vienna)
Number of subjects: 82
Study: 2197091

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 2 weeks
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cefadroxil 1 g twice daily for 2 weeks
Number of subjects: 197
Study: 6243714

Group type: EXPERIMENTAL
Intervention: Topical ether
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 29448221

Group type: EXPERIMENTAL
Intervention: Trip-specific training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No trip-specific training (Untrained)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectation of disturbances
Number of subjects: 0
Study: 26963423

Group type: EXPERIMENTAL
Intervention: Urban forest walking program for 5 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 22985336

Group type: EXPERIMENTAL
Intervention: Manuka honey-impregnated dressings (MHID)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional dressings (CD)
Number of subjects: 63
Study: 23602059

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (particle concentration 300 μg/m3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozone (300 ppb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air (control for diesel exhaust)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air (control for ozone)
Number of subjects: 0
Study: 19652968

Group type: EXPERIMENTAL
Intervention: mIFL combined with bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: mIFL alone
Number of subjects: 0
Study: 17901955

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², bolus fluorouracil 400 mg/m², fluorouracil 46‐h continuous IV infusion 2,400 mg/m², every 2 weeks for a maximum of 12 cycles)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 34
Study: 15753743

Group type: EXPERIMENTAL
Intervention: 6 mL/kg predicted body weight tidal volume
Number of subjects: 84

Group type: COMPARATOR
Intervention: 12 mL/kg predicted body weight tidal volume
Number of subjects: 84
Study: 12027469

Group type: EXPERIMENTAL
Intervention: 4G4G genotype
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: 4G5G genotype
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: 5G5G genotype
Number of subjects: 460
Study: 10845393

Group type: EXPERIMENTAL
Intervention: BCNU + 40 mg tamoxifen (group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BCNU + 100 mg tamoxifen (group C)
Number of subjects: 70

Group type: COMPARATOR
Intervention: BCNU alone (control group A)
Number of subjects: 70
Study: 7577211

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palliative expectant management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidimensional outcome measure
Number of subjects: 0
Study: 1827378

Group type: EXPERIMENTAL
Intervention: protamine‐soluble mixture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Zn‐soluble combination
Number of subjects: 17
Study: 7009310

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside
Number of subjects: 13
Study: 31907649

Group type: EXPERIMENTAL
Intervention: Kinect-based rehabilitation group (KBRG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standardized physical therapy group (SPTG)
Number of subjects: 40
Study: 30641678

Group type: EXPERIMENTAL
Intervention: DASH diet for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diabetic diet for 12 weeks (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diabetic diet (control group)
Number of subjects: 80
Study: 27886522

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (100mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Midazolam (4.5mg)
Number of subjects: 3
Study: 25884846

Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Krill meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 15
Study: 23539076

Group type: EXPERIMENTAL
Intervention: Cold condition (‐14° C)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Moderate condition (6° C)
Number of subjects: 14
Study: 21293122

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 4 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 3 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: QLF (Quantitative Light Fluorescence)
Number of subjects: 16
Study: 19200537

Group type: EXPERIMENTAL
Intervention: Speeded conditions (fast speeded, moderately speeded)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control items (unspeeded condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study 2 (relationship between promiscuous teleology and other variables)
Number of subjects: 0
Study: 16845641

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day, titrated to 90 mg/day after 1 week, then to 120 mg/day after another week, maintained for 4 weeks
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/day
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day, 90 mg/day, 120 mg/day
Number of subjects: 128
Study: 15455235

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS) worn during the 80-min recovery period
Number of subjects: 12
Study: 11099373

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg á kg‐1 body mass
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg á kg‐1 body mass
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9300761

Group type: EXPERIMENTAL
Intervention: Multileaf collimator (MLC) on Philips SL‐25 linear accelerator (6 MV photons)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tray-mounted cerrobend blocks on Philips SL‐75 linear accelerator (5 MV photons)
Number of subjects: 20
Study: 8341134

Group type: EXPERIMENTAL
Intervention: THA (tacrine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 10
Study: 3523711

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS) in high dose (2.1 g daily)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS) in low dose (1.05 g daily)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390